Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider Lisa Bright sold 113 shares of the business’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $119.74, for a total value of $13,530.62. Following the completion of the sale, the insider now owns 23,613 shares in the company, valued at $2,827,420.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Lisa Bright also recently made the following trade(s):

  • On Tuesday, May 2nd, Lisa Bright sold 426 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $114.00, for a total value of $48,564.00.
  • On Monday, April 3rd, Lisa Bright sold 389 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $115.00, for a total value of $44,735.00.
  • On Monday, February 27th, Lisa Bright sold 254 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $119.48, for a total value of $30,347.92.

Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) traded up 1.45% during trading on Thursday, reaching $115.95. The company’s stock had a trading volume of 260,337 shares. Intercept Pharmaceuticals Inc has a 12 month low of $96.63 and a 12 month high of $177.93. The stock’s 50 day moving average price is $112.40 and its 200-day moving average price is $113.04. The firm’s market cap is $2.90 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The business had revenue of $21 million for the quarter, compared to analysts’ expectations of $15.88 million. During the same quarter last year, the firm earned ($5.17) EPS. The firm’s revenue for the quarter was up 4566.7% compared to the same quarter last year. Equities analysts predict that Intercept Pharmaceuticals Inc will post ($14.65) EPS for the current year.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

COPYRIGHT VIOLATION WARNING: This article was posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/05/18/intercept-pharmaceuticals-inc-icpt-insider-sells-13530-62-in-stock.html.

A number of institutional investors have recently made changes to their positions in the stock. Norges Bank purchased a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $17,652,000. ING Groep NV purchased a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $2,120,000. Opus Point Partners Management LLC boosted its position in Intercept Pharmaceuticals by 63.5% in the fourth quarter. Opus Point Partners Management LLC now owns 2,135 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 829 shares in the last quarter. State Street Corp boosted its position in Intercept Pharmaceuticals by 20.2% in the fourth quarter. State Street Corp now owns 751,027 shares of the biopharmaceutical company’s stock valued at $81,600,000 after buying an additional 126,011 shares in the last quarter. Finally, Numeric Investors LLC purchased a new position in Intercept Pharmaceuticals during the fourth quarter valued at approximately $253,000. 82.28% of the stock is currently owned by institutional investors and hedge funds.

A number of brokerages have recently commented on ICPT. Oppenheimer Holdings Inc. set a $200.00 price target on Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Saturday, February 11th. Cowen and Company restated an “outperform” rating and issued a $225.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, February 10th. Robert W. Baird restated a “positive” rating on shares of Intercept Pharmaceuticals in a report on Friday, February 10th. Cantor Fitzgerald set a $60.00 price target on Intercept Pharmaceuticals and gave the company a “sell” rating in a report on Thursday, May 4th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $223.00 price target (up from $221.00) on shares of Intercept Pharmaceuticals in a report on Friday, May 5th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $188.37.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.